Pharmaceuticals

Growth In The Preeclampsia Drugs Market Is Being Driven By Booming Digital Health Fueling The Growth Of The E-Pharmacy

May 4, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

What Is The Projected Increase In Market Value Of The Preeclampsia Drugs Market During 2026–2030?

The preeclampsia drugs market has experienced rapid expansion in recent years. It is projected to increase from $1.37 billion in 2025 to $1.52 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.6%. Historically, this growth has been influenced by factors such as limited awareness of preeclampsia management, a reliance on traditional therapies, the absence of advanced monitoring technologies, inadequate hospital infrastructure, and low investment in maternal health drugs.

The preeclampsia drugs market size is expected to undergo significant expansion in the coming years, projected to reach $2.37 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.8%. This growth during the forecast period can be attributed to advancements in drug formulations, the expansion of healthcare infrastructure, a rising demand for outpatient maternal care, the integration of digital health solutions, and increased research and development in precision medicine for pregnancy complications. Major trends anticipated in this period include the rising incidence of preeclampsia among pregnant women, the development of novel antihypertensive drugs, an increased focus on maternal and fetal health monitoring, the growth of hospital pharmacy and specialty clinics distribution, and the adoption of combination therapies for severe cases.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=13025&type=smp

Which Primary Drivers Are Impacting The Preeclampsia Drugs Market Growth?

The preeclampsia drug market is projected to grow due to the increasing incidence of diabetes among pregnant women. Diabetes is a chronic metabolic disease characterized by high blood glucose levels, while preeclampsia is a harmful pregnancy condition involving elevated blood pressure and organ damage. Metformin, a medication for preeclampsia, is frequently prescribed for pregnant women with preterm preeclampsia. An illustration of this trend comes from June 2024, when the National Health Service, a UK-based government department, revealed that in 2023, 549,000 new individuals in England were identified as being at risk of developing type 2 diabetes. This increased the total number of people with non-diabetic hyperglycemia, or pre-diabetes, registered with a GP to 3,615,330, which signifies a nearly 20% rise from 3,065,825 recorded in 2022. Consequently, the increasing prevalence of diabetes cases in pregnant women is set to fuel the preeclampsia drug market.

What Segment Categories Shape The Preeclampsia Drugs Market Segment Landscape?

The preeclampsia drugs market covered in this report is segmented –

1) By Type: Mild Preeclampsia, Severe Preeclampsia

2) By Treatment: Medication to Lower Hypertension (B.P), Corticosteroids, Anticonvulsants Medication

3) By Route of Administration: Oral, Parenteral, Other Route of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacies, Other Distribution Channels

5) By End-User: Hospitals, Specialty Clinics, Diagnostic Centers, Other End-Users

Subsegments:

1) By Mild Preeclampsia: Blood Pressure Management

2) By Severe Preeclampsia: Antihypertensive Medications, Magnesium Sulfate Therapy

Which Trends Are Contributing To Changes In The Preeclampsia Drugs Market?

Leading firms within the preeclampsia medicine market are concentrating on creating sophisticated therapies, like small interfering RNA (siRNA) treatments, aiming to tackle significant unmet medical requirements through innovative modes of action. Investigational siRNA therapies represent a category of medications engineered to silence or deactivate particular genes implicated in disease causation, thereby providing a focused treatment strategy. An example of this is seen in March 2023, when Comanche Biopharma Corp., a biopharmaceutical company located in the US, announced the Food and Drug Administration (FDA)’s approval of an investigational new drug (IND) application for CBP-4888, Comanche’s distinctive siRNA therapy for preeclampsia. CBP-4888 functions as a subcutaneously administered siRNA treatment that decreases the production of soluble fms-like tyrosine kinase-1 (sFLT1) within the placenta. The primary etiological factor for preeclampsia is the placenta’s excessive generation of the protein sFLT1, which subsequently enters the maternal bloodstream. This therapy, CBP-4888, has the potential to mitigate preeclampsia symptoms, including elevated blood pressure and organ impairment, and could enable a safe prolongation of pregnancy.

Who Are The Companies Operating Across The Preeclampsia Drugs Market Value Chain?

Major companies operating in the preeclampsia drugs market are AbbVie Inc., Pfizer Inc., Johnson & Johnson Co, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Sanofi S.A., AstraZeneca plc, GlaxoSmithKline PLC, Takeda Pharmaceuticals Company Limited, Eli Lilly and Company, Boehringer Ingelheim Group, Viatris Inc., Teva Pharmaceutical Industries Ltd., Baxter International Inc., Otsuka Pharmaceutical Co. Ltd., Mallinckrodt Pharmaceuticals Limited, Union Chimique Belge SA, Kyowa Kirin Co Ltd, Comanche Biopharma Corp

Get The Full Preeclampsia Drugs Market Report:

https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report

Which Region Is The Top Contributor To The Preeclampsia Drugs Market By Share?

North America was the largest region in the preeclampsia drugs market in 2025. The regions covered in the preeclampsia drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Preeclampsia Drugs Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report

Browse Through More Reports Similar to the Global Preeclampsia Drugs Market 2026, By The Business Research Company

Preeclampsia Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/preeclampsia-drugs-global-market-report

Fertility Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/fertility-drugs-global-market-report

Epilepsy Drugs Market Report 2026

https://www.thebusinessresearchcompany.com/report/epilepsy-drugs-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795